FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular to a method for monitoring production of polyspecific binding protein and one or more molecules with mismatched cell line. In some embodiments, the methods include determining the amount of a polyspecific binding protein and one or more molecules with mismatch in a medium for culturing cells by means of exclusion super-efficient liquid chromatography under denaturation conditions and mass spectrometry (SE-UPLC-MS). In some embodiments, the polyspecific binding protein is a polyspecific antibody, an antibody fragment or a protein which is a fusion product with Fc.
EFFECT: invention provides a method of monitoring or analysing the production of an antibody or antibody derivatives which contain several molecules differing in molecular weight.
15 cl, 11 dwg, 2 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO CD38 AND COMBINATIONS WITH ANTIBODIES TO CD3 AND CD28 | 2018 |
|
RU2812910C2 |
| POLYSPECIFIC POLYPEPTIDE CONSTRUCTS WITH LIMITED BINDING TO CD3 AND METHODS OF THEIR APPLICATION | 2018 |
|
RU2813816C2 |
| TRISPECIFIC BINDING PROTEINS BINDING CD38, CD28 AND CD3, AS WELL AS METHODS OF USE FOR TREATING VIRAL INFECTION | 2019 |
|
RU2820351C2 |
| PREFERENTIAL PAIRING OF ANTIBODY DOMAIN | 2018 |
|
RU2792440C2 |
| TRI- OR TETRASPECIFIC ANTIBODIES | 2010 |
|
RU2570633C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2788531C2 |
| BISPECIFIC, TETRAVALENT ANTIGEN BINDING PROTEINS | 2010 |
|
RU2604189C2 |
| POLYVALENT BINDING PROTEINS FOR ACTIVATION OF NATURAL KILLER CELLS AND THEIR THERAPEUTIC APPLICATION FOR TREATMENT OF MALIGNANT NEOPLASM | 2018 |
|
RU2809125C2 |
| PROTEIN BINDING WITH NKG2D, CD16 AND WITH TUMOR-SPECIFIC ANTIGEN | 2018 |
|
RU2826991C2 |
| METHOD FOR OBTAINING BI-SPECIFIC ANTIBODIES, BI-SPECIFIC ANTIBODIES AND THERAPEUTIC APPLICATION OF SUCH ANTIBODIES | 2018 |
|
RU2795240C2 |
